Research Keyword: adverse events

Multidisciplinary Integrative Medicine Approach for Cancer Patients: A Multicenter Retrospective Study

This study shows that when cancer patients use complementary treatments like mushroom supplements, vitamins, and probiotics alongside their cancer medications under doctor supervision, they experience fewer side effects and better quality of life. Almost 93% of patients had no side effects from these supplements, and many reported less fatigue and better overall wellness. The key finding is that patients should work with their medical team rather than self-prescribing these treatments to avoid dangerous interactions.

Read More »

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review

This review examines two emerging psychiatric treatments—ketamine and psilocybin—for treating hard-to-treat mental health conditions in children and teenagers. Both work by affecting brain chemicals differently than traditional medications and can provide rapid symptom relief, sometimes within hours or days rather than weeks. The study found promising results for depression, anxiety, PTSD, and bipolar disorder, though researchers emphasize that more studies are needed to ensure these treatments are safe for developing brains and that careful ethical guidelines must be established.

Read More »

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

This study examined whether taking the antidepressant escitalopram before using psilocybin affects the drug’s effects. Twenty-three healthy participants took either escitalopram or placebo for two weeks, then received a dose of psilocybin. Surprisingly, escitalopram did not reduce the positive mood effects of psilocybin and actually reduced some negative side effects like anxiety and bad feelings. The combination appeared safe with no increased cardiovascular risks.

Read More »

When Nature Meets Oncology: Unraveling Herb–Drug Interactions in Cancer Therapy

Many cancer patients use herbal supplements and natural products alongside their cancer treatments without telling their doctors, which can be dangerous. Some natural products like St. John’s Wort and grapefruit juice significantly alter how the body processes cancer medications, potentially making treatments ineffective or toxic. The review provides guidance on which natural products are safe to use with cancer therapy and which should be avoided completely, emphasizing the importance of open communication between patients and healthcare providers.

Read More »

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

Researchers tested whether combining psilocybin therapy with mindfulness training could better treat depression and burnout in frontline healthcare workers than mindfulness training alone. Twenty-five doctors and nurses participated in the study, with some receiving mindfulness training combined with psilocybin therapy in a group setting, while others received mindfulness training only. After two weeks, those who received the combined treatment showed significantly greater improvements in depression symptoms and burnout, with no serious side effects reported. This suggests that psilocybin-assisted therapy combined with mindfulness training could be a promising treatment for depression and burnout among healthcare professionals.

Read More »

Psychedelic-assisted therapy – supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics

This paper critically examines recent clinical trials testing MDMA and psilocybin for treating PTSD and depression. While these trials reported promising results, the author identifies serious scientific and ethical problems: participants could tell whether they received the drug or placebo due to its strong effects, researchers and therapists who strongly believed in the treatment may have unconsciously influenced patient responses, and negative side effects may have been downplayed. The author argues that without fixing these problems, the entire field of psychedelic therapy research could lose credibility.

Read More »

Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing

Diamond Shruumz mushroom-based edible products caused severe illnesses in consumers and were recalled by the FDA in June 2024. Researchers discovered that despite the recall, many online sellers continued to advertise and sell these products across social media and websites. The study found that even two weeks after the recall, about one-third of the websites still successfully completed product sales, showing how difficult it is for regulators to enforce recalls on the internet.

Read More »

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Read More »

Psychedelic-assisted psychotherapy: The need to monitor adverse events

While psychedelics show promise for treating depression and other mental health conditions, researchers need better systems to monitor and report any harmful effects they might cause. This paper calls for more careful, consistent tracking of both physical changes (like blood pressure) and psychological experiences during psychedelic therapy. The authors emphasize that safety monitoring should continue even after patients leave the clinic and that women may experience different side effects than men.

Read More »

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

This review examined how well liposomal amphotericin B (a fungal medication) works to prevent serious fungal infections in children. Researchers looked at 20 studies involving over 2000 children and found that about 7% still developed fungal infections despite the medication, with common side effects being low potassium levels and liver problems. The main finding is that doctors use this medication in very different ways, and we need better research to figure out the best dosing strategy for children.

Read More »
Scroll to Top